MedTrace Logo

Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

NCT01659580 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1004

Last updated 2017-03-09

No results posted yet for this study

Summary

This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable angina pectoris.

Conditions

  • Angina Pectoris

Interventions

DRUG

T89 high dose

225mg bid

DRUG

T89 Low dose

150mg bid

DRUG

Sanqi+Bingpian

225 mg bid

DRUG

Placebo

225mg bid

Sponsors & Collaborators

  • Tasly Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Henry He Sun, PhD · Tasly Group, Co. Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States
  • Belarus
  • Canada
  • Georgia
  • Mexico
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01659580 on ClinicalTrials.gov